- FDA advisors recommend first-ever RSV vaccine from Pfizer, despite possible Guillain-Barre risks CNBC
- FDA flags Guillain-Barré risks for GSK, Pfizer RSV shots, but just one will need safety trial FierceBiotech
- FDA panel narrowly backs Pfizer RSV vaccine for older adults ABC News
- Pfizer’s RSV Vaccine Wins US Panel’s Backing for Safety in Older People Bloomberg
- View Full Coverage on Google News
Categories